The Medical Letter on Drugs and Therapeutics
FROM
ISSUE
942
February 17, 1995
View Complete Issue         Table of Contents 2019 
Fluvoxamine for Obsessive-Compulsive Disorder
Subscribers: Log in to read full article.  Not a subscriber?  Subscribe or purchase article.
Fluvoxamine for Obsessive-Compulsive Disorder
February 17, 1995 (Issue: 942)
Fluvoxamine (Luvox - Solvay), a selective serotonin reuptake inhibitor (SSRI), has been approved for treatment of obsessive-compulsive disorder (OCD) by the US Food and Drug Administration. Fluoxetine (Prozac), another SSRI antidepressant, and ...more
The Medical Letter is a subscriber-funded nonprofit organization that publishes critical appraisals of new prescription drugs and comparative reviews of drugs for common diseases.

Would you like to read the rest of this article?  Gain access below.

Subscribe
Subscriptions to The Medical Letter on Drugs and Therapeutics include:
  • Print version published and mailed biweekly (26 issues/year)
  • Unlimited online access to current and past issues (1988 - present)
  • Mobile App
  • FREE online per issue CME/CE
Purchase this article:
Title: Fluvoxamine for Obsessive-Compulsive Disorder
Article code: 942a
 Electronic, downloadable article - $45


Gain access through your organization
Ask your librarian to consider an Institutional Subscription to The Medical Letter.